TPST Stock

Biotech

Tempest Therapeutics (TPST) Stock Jumps 83% on FDA Phase 3 Trial News

Tempest Therapeutics (NASDAQ: TPST), a clinical-stage biotechnology firm focused on innovative cancer therapies, announced a significant milestone on Thursday as…

Read More »
Back to top button